Eldelumab

• Description :

  Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type) . Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease[1][2].

• Product Name Alternative :

  BMS-936557; MDX-1100

• UNSPSC :

  12352203

• Target :

  CXCR

• Type :

  Inhibitory Antibodies

• Related Pathways :

  GPCR/G Protein; Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/eldelumab.html

• Purity :

  99.50

• Solubility :

  10 mM in DMSO

• Smiles :

  [Eldelumab]

• Molecular Weight :

  (146.64 kDa)

• References & Citations :

  [1]Gupta RK, et al. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium. PLoS One. 2021 Sep 28;16 (9) :e0257784. |[2]Asquith DL, et al. Targeting cell migration in rheumatoid arthritis. Curr Opin Rheumatol. 2015 Mar;27 (2) :204-11.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [946414-98-8]